Cannabis use and cardiometabolic risk in schizophrenia
In schizophrenia, cannabis use was associated with lower rates of both metabolic syndrome and central obesity. While these findings support emerging evidence of metabolic differences in cannabis users, the cross-sectional design precludes conclusions regarding causality. Longitudinal studies are needed to clarify long-term metabolic effects and guide targeted interventions.
Authors
- Victoria Kiriaki Arnet
- Cherrie Galletly (ORCID: https://orcid.org/0000-0001-6185-9677)
- Jai Ethan Paris (ORCID: https://orcid.org/0000-0003-0178-6706)
- Olivia Laurendi
Institutions
- SA Health (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Schizophrenia Research
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.schres.2025.11.013
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00